Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Madrigal Pharmaceuticals Inc's Business Segments
Madrigal Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 311
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 311 | 100% |
Description of Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of serious diseases that are impacting the lives of patients around the world. The company was founded in 2011 with the goal of using its expertise in the field of liver metabolism to develop novel drugs that can help patients with various forms of liver and cardiovascular diseases.
The company's flagship product is MGL-3196, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from non-alcoholic steatohepatitis (NASH), a serious liver disease that is characterized by inflammation and the accumulation of fat in the liver. The drug has shown significant promise in early clinical trials, and it is currently being evaluated in phase 3 clinical trials for the treatment of NASH.
Madrigal is also developing other products that are designed to address other liver and cardiovascular diseases. One of the company's other products is MGL-3745, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from dyslipidemia. Dyslipidemia is a condition that is characterized by high levels of cholesterol and triglycerides in the blood, which can lead to serious health problems such as heart disease and stroke.
In addition to its drug development efforts, Madrigal is also actively engaged in research and development activities aimed at discovering new and innovative therapies for other serious diseases. The company has a team of experienced researchers and scientists who are working to identify new drug targets and develop new drug candidates that can help patients suffering from a range of diseases.
Overall, Madrigal Pharmaceuticals Inc. is a highly innovative and promising biopharmaceutical company that is focused on developing new and effective treatments for serious diseases. With its focus on liver and cardiovascular diseases and its highly experienced team of researchers and scientists, the company is well-positioned to make a significant impact on the lives of patients around the world.
The company's flagship product is MGL-3196, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from non-alcoholic steatohepatitis (NASH), a serious liver disease that is characterized by inflammation and the accumulation of fat in the liver. The drug has shown significant promise in early clinical trials, and it is currently being evaluated in phase 3 clinical trials for the treatment of NASH.
Madrigal is also developing other products that are designed to address other liver and cardiovascular diseases. One of the company's other products is MGL-3745, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from dyslipidemia. Dyslipidemia is a condition that is characterized by high levels of cholesterol and triglycerides in the blood, which can lead to serious health problems such as heart disease and stroke.
In addition to its drug development efforts, Madrigal is also actively engaged in research and development activities aimed at discovering new and innovative therapies for other serious diseases. The company has a team of experienced researchers and scientists who are working to identify new drug targets and develop new drug candidates that can help patients suffering from a range of diseases.
Overall, Madrigal Pharmaceuticals Inc. is a highly innovative and promising biopharmaceutical company that is focused on developing new and effective treatments for serious diseases. With its focus on liver and cardiovascular diseases and its highly experienced team of researchers and scientists, the company is well-positioned to make a significant impact on the lives of patients around the world.
Madrigal Pharmaceuticals Inc: Extensive Overview of Segments, Products, and Services
Company Overview:
Madrigal Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing innovative therapies aimed at treating cardiovascular and metabolic diseases. With a strong emphasis on developing small molecule drugs, Madrigal targets specific metabolic pathways that play significant roles in disease progression, particularly in areas related to liver health, cardiovascular function, and metabolic regulation.
Segments
Madrigal Pharmaceuticals operates primarily within the pharmaceutical industry, specifically within the biopharmaceutical sector. The company focuses on three major therapeutic areas:
1. Liver Disease: Targeting conditions such as non-alcoholic steatohepatitis (NASH) and other liver-related diseases, which represent significant unmet medical needs.
2. Cardiovascular Disease: Addressing a range of cardiovascular conditions, particularly those related to lipid metabolism and cholesterol management.
3. Metabolic Disease: Focusing on disorders related to abnormal metabolism, particularly those that affect lipid and glucose levels in the body.
Products
Madrigal Pharmaceuticals has a robust pipeline of products that aim to alleviate the burden of various diseases associated with abnormal metabolism. Some of the key products include:
1. MGL-3196:
- Description: This is an innovative once-daily oral therapy specifically designed to treat non-alcoholic steatohepatitis (NASH).
- Mechanism: By regulating fat levels in the liver and reducing inflammation, MGL-3196 aims to reverse the progression of liver damage associated with NASH, improving liver function and overall liver health.
- Development Status: The product has undergone extensive clinical trials, showcasing promising efficacy and safety profiles.
2. MGL-3745:
- Description: MGL-3745 is a novel oral therapy aimed at treating hypercholesterolemia, particularly for patients with elevated low-density lipoprotein (LDL) cholesterol levels.
- Mechanism: This drug works by enhancing the clearance of LDL cholesterol from the bloodstream, leading to reduced cholesterol levels and mitigating the associated cardiovascular risks.
- Benefits: It addresses a significant cardiovascular risk factor, offering a potential treatment option for patients with challenging cholesterol profiles.
3. MGL-3198:
- Description: Formulated as a once-daily oral therapy, MGL-3198 is designed to treat diabetic dyslipidemia, characterized by dysregulated lipid levels often seen in diabetes.
- Mechanism: It works by modulating lipid metabolism to improve abnormal lipid levels, fostering better metabolic control in patients with diabetes.
- Target Population: This therapy is particularly valuable for diabetic patients who are susceptible to cardiovascular complications due to dyslipidemia.
Services
In addition to its pharmaceutical products, Madrigal Pharmaceuticals provides a range of critical services to support the development, manufacturing, and commercialization of its therapies:
1. Clinical Trial Management:
- Madrigal oversees all aspects of clinical trials, from planning and execution to monitoring and reporting. This includes regulatory affairs to ensure compliance with health authorities and data management that ensures the accuracy and integrity of trial results.
2. Manufacturing and Supply Chain Management:
- The company is involved in the production process of its pharmaceutical products, ensuring that all manufacturing adheres to stringent quality standards. Moreover, Madrigal manages the supply chain logistics to guarantee timely and efficient distribution of products globally, facilitating access for healthcare providers and patients.
3. Marketing and Sales:
- Madrigal Pharmaceuticals engages in strategic marketing initiatives to promote its drugs and support their adoption in the clinical community. The sales teams work closely with healthcare professionals to ensure that the products are prescribed effectively and utilized optimally, contributing to improved patient outcomes.
Conclusion
In summary, Madrigal Pharmaceuticals Inc stands at the forefront of biopharmaceutical innovation, focusing on developing and commercializing therapies for liver disease, cardiovascular disease, and metabolic disorders. With a strong pipeline of specialized products such as MGL-3196, MGL-3745, and MGL-3198, coupled with comprehensive services including clinical trial management, manufacturing, and marketing, Madrigal is poised to make significant impacts in the treatment of these critical health issues. The companys commitment to addressing unmet medical needs reflects its broader mission of improving patient care and advancing health outcomes through cutting-edge biopharmaceutical solutions.
Company Overview:
Madrigal Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing innovative therapies aimed at treating cardiovascular and metabolic diseases. With a strong emphasis on developing small molecule drugs, Madrigal targets specific metabolic pathways that play significant roles in disease progression, particularly in areas related to liver health, cardiovascular function, and metabolic regulation.
Segments
Madrigal Pharmaceuticals operates primarily within the pharmaceutical industry, specifically within the biopharmaceutical sector. The company focuses on three major therapeutic areas:
1. Liver Disease: Targeting conditions such as non-alcoholic steatohepatitis (NASH) and other liver-related diseases, which represent significant unmet medical needs.
2. Cardiovascular Disease: Addressing a range of cardiovascular conditions, particularly those related to lipid metabolism and cholesterol management.
3. Metabolic Disease: Focusing on disorders related to abnormal metabolism, particularly those that affect lipid and glucose levels in the body.
Products
Madrigal Pharmaceuticals has a robust pipeline of products that aim to alleviate the burden of various diseases associated with abnormal metabolism. Some of the key products include:
1. MGL-3196:
- Description: This is an innovative once-daily oral therapy specifically designed to treat non-alcoholic steatohepatitis (NASH).
- Mechanism: By regulating fat levels in the liver and reducing inflammation, MGL-3196 aims to reverse the progression of liver damage associated with NASH, improving liver function and overall liver health.
- Development Status: The product has undergone extensive clinical trials, showcasing promising efficacy and safety profiles.
2. MGL-3745:
- Description: MGL-3745 is a novel oral therapy aimed at treating hypercholesterolemia, particularly for patients with elevated low-density lipoprotein (LDL) cholesterol levels.
- Mechanism: This drug works by enhancing the clearance of LDL cholesterol from the bloodstream, leading to reduced cholesterol levels and mitigating the associated cardiovascular risks.
- Benefits: It addresses a significant cardiovascular risk factor, offering a potential treatment option for patients with challenging cholesterol profiles.
3. MGL-3198:
- Description: Formulated as a once-daily oral therapy, MGL-3198 is designed to treat diabetic dyslipidemia, characterized by dysregulated lipid levels often seen in diabetes.
- Mechanism: It works by modulating lipid metabolism to improve abnormal lipid levels, fostering better metabolic control in patients with diabetes.
- Target Population: This therapy is particularly valuable for diabetic patients who are susceptible to cardiovascular complications due to dyslipidemia.
Services
In addition to its pharmaceutical products, Madrigal Pharmaceuticals provides a range of critical services to support the development, manufacturing, and commercialization of its therapies:
1. Clinical Trial Management:
- Madrigal oversees all aspects of clinical trials, from planning and execution to monitoring and reporting. This includes regulatory affairs to ensure compliance with health authorities and data management that ensures the accuracy and integrity of trial results.
2. Manufacturing and Supply Chain Management:
- The company is involved in the production process of its pharmaceutical products, ensuring that all manufacturing adheres to stringent quality standards. Moreover, Madrigal manages the supply chain logistics to guarantee timely and efficient distribution of products globally, facilitating access for healthcare providers and patients.
3. Marketing and Sales:
- Madrigal Pharmaceuticals engages in strategic marketing initiatives to promote its drugs and support their adoption in the clinical community. The sales teams work closely with healthcare professionals to ensure that the products are prescribed effectively and utilized optimally, contributing to improved patient outcomes.
Conclusion
In summary, Madrigal Pharmaceuticals Inc stands at the forefront of biopharmaceutical innovation, focusing on developing and commercializing therapies for liver disease, cardiovascular disease, and metabolic disorders. With a strong pipeline of specialized products such as MGL-3196, MGL-3745, and MGL-3198, coupled with comprehensive services including clinical trial management, manufacturing, and marketing, Madrigal is poised to make significant impacts in the treatment of these critical health issues. The companys commitment to addressing unmet medical needs reflects its broader mission of improving patient care and advancing health outcomes through cutting-edge biopharmaceutical solutions.